Key facts
- It has raised $46.5M; the latest was Merger/Acquisition in Feb 2026.
- SpotItEarly has filed 1 Form D with the SEC, most recently Aug 2025 ($10K sold to 1 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for SpotItEarly
- ·The full record, as it builds
Funding rounds
No funding rounds for SpotItEarly are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SpotItEarly
Developer of cancer detection technology designed to detect cancer at its early stages and save people's lives. The company combines scent-based bio-detectors together with a proprietary artificial intelligence-driven platform, enabling healthcare professionals to offer suitable tests for early cancer detection for patients.
- Sector
- Healthcare
- HQ
- Englewood, NJ, United States
- Founded
- 2020
- Employees
- 33
- Website
- spotitearly.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
SpotItEarly doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SpotItEarly shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SpotItEarly in its N-PORT filings yet. We sweep new filings monthly.